1. Ambrisentan is ineffective in delaying disease progression in idiopathic pulmonary fibrosis (IPF).
2. Compared to placebo, Ambrisentan is associated with increased risk of disease progression and respiratory hospitalization.
Evidence rating level: 1 (Excellent)
Study rundown: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive form of fibrotic interstitial lung disease with unknown etiology. IPF is a diagnosis of exclusion, and has a median survival of 3 years after diagnosis. There are no approved drug therapies in the US that have been repeatedly proven efficacious. Therefore, there is a great deal of interest in potential therapies for IPF.
Read the entire article at: